A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.
Kaneko N, Loughrey CM, Smith G, Matsuda R, Hasunuma T, Mark PB, Toda M, Shinozaki M, Otani N, Kayley S, Da Silva Costa A, Martin TP, Dobi S, Saxena P, Shimamoto K, Ishikawa T, Kambayashi R, Riddell A, Elliott EB, McCarroll CS, Sakai T, Mitsuhisa Y, Hirano S, Kitai T, Kusano K, Inoue Y, Nakamura M, Kikuchi M, Toyoda S, Taguchi I, Fujiwara T, Sugiyama A, Kumagai Y, Iwata K.
Kaneko N, et al. Among authors: martin tp.
Br J Pharmacol. 2024 Sep;181(18):3401-3419. doi: 10.1111/bph.16379. Epub 2024 May 21.
Br J Pharmacol. 2024.
PMID: 38773354
Clinical Trial.